Limits...
Retrospective public health impact of a quadrivalent influenza vaccine in the United States.

Crépey P, de Boer PT, Postma MJ, Pitman R - Influenza Other Respir Viruses (2015)

Bottom Line: Elderly (≥65 years) and young seniors (50-64 years) benefit most from QIV, with 21% and 18% reductions in B lineage cases.Reducing cross-protection to 50%, 30%, and 0% of the VE of the matched vaccine improves the relative benefit of QIV to 25%, 30%, and 34% less B lineage cases.Using a dynamic retrospective framework with real-life vaccine mismatch, our analysis shows that QIV routine vaccination in the United States has the potential to substantially reduce the number of influenza infections, even with relatively high estimates of TIV-induced cross-protection.

View Article: PubMed Central - PubMed

Affiliation: EHESP Rennes, Sorbonne Paris-cité, Paris, France.

No MeSH data available.


Related in: MedlinePlus

Sensitivity analysis of the duration of immunity acquired upon infection. QIV, quadrivalent influenza vaccine; TIV, trivalent influenza vaccine.
© Copyright Policy - open-access
Related In: Results  -  Collection

License
getmorefigures.php?uid=PMC4549101&req=5

fig06: Sensitivity analysis of the duration of immunity acquired upon infection. QIV, quadrivalent influenza vaccine; TIV, trivalent influenza vaccine.

Mentions: Lastly, we varied duration of immunity acquired by infection from 6 to 18 years. Results displayed in Figure6 show that an increased duration of acquired immunity tends to decrease QIV impact. However, the relation seems to be asymptotic; increasing the duration from 12 to 18 years only reduces QIV impact by <1% (all age groups).


Retrospective public health impact of a quadrivalent influenza vaccine in the United States.

Crépey P, de Boer PT, Postma MJ, Pitman R - Influenza Other Respir Viruses (2015)

Sensitivity analysis of the duration of immunity acquired upon infection. QIV, quadrivalent influenza vaccine; TIV, trivalent influenza vaccine.
© Copyright Policy - open-access
Related In: Results  -  Collection

License
Show All Figures
getmorefigures.php?uid=PMC4549101&req=5

fig06: Sensitivity analysis of the duration of immunity acquired upon infection. QIV, quadrivalent influenza vaccine; TIV, trivalent influenza vaccine.
Mentions: Lastly, we varied duration of immunity acquired by infection from 6 to 18 years. Results displayed in Figure6 show that an increased duration of acquired immunity tends to decrease QIV impact. However, the relation seems to be asymptotic; increasing the duration from 12 to 18 years only reduces QIV impact by <1% (all age groups).

Bottom Line: Elderly (≥65 years) and young seniors (50-64 years) benefit most from QIV, with 21% and 18% reductions in B lineage cases.Reducing cross-protection to 50%, 30%, and 0% of the VE of the matched vaccine improves the relative benefit of QIV to 25%, 30%, and 34% less B lineage cases.Using a dynamic retrospective framework with real-life vaccine mismatch, our analysis shows that QIV routine vaccination in the United States has the potential to substantially reduce the number of influenza infections, even with relatively high estimates of TIV-induced cross-protection.

View Article: PubMed Central - PubMed

Affiliation: EHESP Rennes, Sorbonne Paris-cité, Paris, France.

No MeSH data available.


Related in: MedlinePlus